[Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy].
OBJECTIVE
Chronic hepatitis B virus (HBV) infection increases the prevalence of liver damage and related death of malignant tumor patients. This study was to investigate the prevalence of liver damage and clinical results in lymphoma patients with chronic HBV infection after standard chemotherapy, and assess high risk factors associated with liver damage for better guidance in clinic.


METHODS
Records of 116 lymphoma patients with chronic HBV infection, treated with standard chemotherapy from Jan. 1985 to Jan. 2002 in Cancer Center of Sun Yat-sen University, were reviewed to analyze the prevalence of liver damage, clinical results, and related high risk factors.


RESULTS
Of the 116 patients, 60 (51.7%) suffered liver damage. According to WHO criteria of liver toxicity, 4 (3.4%) were in grade I, 14 (12.1%) in grade II, 15 (12.9%) in grade III, and 27 (23.3%) in grade IV. After treatment for liver damage, 11 (9.5%) patients completed chemotherapy without delay, 27(23.3%) completed chemotherapy with delay of more than 8 days, 16 (13.8%) terminated chemotherapy, 6 (5.2%) died. Logistic multivariate analysis showed that steroid was a high risk factor of liver damage after chemotherapy.


CONCLUSIONS
The prevalence of liver damage is high in lymphoma patients with chronic HBV infection after standard chemotherapy, which led to treatment delay or discontinue, even death. Steroid is a high risk of liver damage.
Li
Yu-Hong
YH
State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong 510060, P. R. China. yuhongli@163.net
He
Yi-Fu
YF
Wang
Feng-Hua
FH
Lin
Xu-Bin
XB
Xia
Zhong-Jun
ZJ
Sun
Xiao-Fei
XF
Lin
Tong-Yu
TY
Huang
Hui-Qiang
HQ
Zhang
Li
L
Xu
Rui-Hua
RH
Jiang
Wen-Qi
WQ
Guan
Zhong-Zhen
ZZ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D019694:Hepatitis B, Chronic / Q000209:etiology* / Q000473:pathology; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008099:Liver / Q000473:pathology*; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D013256:Steroids / Q000009:adverse effects* / Q000627:therapeutic use
D013256:Steroids; D004317:Doxorubicin